Ibrutinib for Relapsed / Refractory CLL: A UK and Ireland Analysis of Outcomes in 315 patients

Autor: Jacob, A, Bloor, A, Whiteway, A, Milne, AE, Kirkwood, AA, Hodson, A, Duncombe, AS, Schuh, A, von Barsewisch, B, Fegan, C, Fox, CP, Pocock, C, William, C, Dearden, C, Hutchinson, C, Balotis, C, De Lord, C, Kennedy, DB, Tucker, D, Vendenberghe, E, Maughan, E, Kumar, E, McNichol, F, Scott, F, Forconi, F, Campbell, G, Follows, GA, Pratt, G, Knight, H, Parry, H, Ringshausen, I, Whalley, I, Nielson, J, Allen, J, Arnold, J, Gribbon, J, Wallis, J, Blundell, J, Cwynarski, K, Bowles, KM, Ewings, M, Karanth, M, Dyer, MJ, Hamblin, M, Leach, M, Badat, M, Mir, N, Morley, N, Bienz, N, Philpott, N

In 2014, ibrutinib was made available for relapsed/refractory chronic lymphocytic leukaemia (CLL) patients. The UK CLL Forum collected data from UK/Ireland patients with a minimum of 1 year follow-up with pre-planned primary endpoints; the number of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1366::1b5dc6a041890c04f5fe51fd38045105
https://ueaeprints.uea.ac.uk/id/eprint/61047/

Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma.

Autor: Sesques P; Hematology Department, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69410, Pierre Bénite, Lyon, France., Kirkwood AA; Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK., Kwon M; Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Rejeski K; Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany., Jain MD; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, USA., Di Blasi R; Hematology Department, Hôpital Saint Louis, Paris, France., Brisou G; Hematology Department, Institut Paoli Calmettes, Marseille, France., Gros FX; Hematology Department, CHU de Bordeaux, Bordeaux, France., le Bras F; Hematology Department, Hôpital Henri Mondor, Créteil, France., Bories P; Hematology Department, CHU de Toulouse, Toulouse, France., Choquet S; Hematology Department, Hôpital de la Pitié Salpêtrière and AP-HP Sorbonne Université, Paris, France., Rubio MT; Hematology Department, CNRS UMR 7365, CHRU de Nancy, Nancy, France., Iacoboni G; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., O'Reilly M; Department of Haematology, University College London Hospitals, London, UK., Casasnovas RO; Hematology Department, CHU de Dijon and INSERM 1231, Dijon, France., Bay JO; Hematology Department, CHU de Clermont Ferrand, Clermont-Ferrand, France., Mohty M; Hematology Department, Hôpital Saint Antoine, Inserm UMRs 938, Sorbonne University, Paris, France., Joris M; Hematology Department, CHU d'Amiens, Amiens, France., Abraham J; Hematology Department, CHU de Limoges, Limoges, France., Castilla Llorente C; Hematology Department, Gustave Roussy Cancer Campus, Villejuif, Paris, France., Loschi M; Hematology Department, CHU de Nice, Nice, France., Carras S; Hematology Department, Institute for Advanced Biosciences (INSERM U1209, CNRS UMR 5309), CHU de Grenoble and University Grenoble-Alpes, La Tronche, France., Chauchet A; Hematology Department, CHU de Besançon, Besançon, France., La Rochelle LD; Hematology Department, CHU de Tours, Tours, France., Hermine O; Hematology Department, Hôpital Necker, Paris, France., Guidez S; Hematology Department, CHU de Poitiers, Poitiers, France., Cony-Makhoul P; Medical and Scientific Affairs Department, LYSARC, Lyon, France., Fogarty P; Biostatistics Department, LYSARC, Lyon, France., Le Gouill S; Hematology Department, Institut Curie, Paris, France., Morschhauser F; Hematology Department, CHU de Lille, Lille, France.; ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille University, Lille, France., Gastinne T; Hematology Department, CHU de Nantes, Nantes, France., Cartron G; Hematology Department, CHU de Montpellier and UMR-CNRS, Montpellier, France., Subklewe M; Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany., Locke FL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, USA., Sanderson R; Department of Haematology, King's College Hospital, London, UK., Barba P; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Houot R; Hematology Department, CHU de Rennes, Rennes, France., Bachy E; Hematology Department, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69410, Pierre Bénite, Lyon, France. emmanuel.bachy@chu-lyon.fr.; Lymphoma Immuno-Biology, CIRI, Inserm U1111, Lyon, France. emmanuel.bachy@chu-lyon.fr.

Publikováno v: Journal of hematology & oncology [J Hematol Oncol] 2024 Aug 06; Vol. 17 (1), pp. 61. Date of Electronic Publication: 2024 Aug 06.

Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.

Autor: Kuhnl A; Department of Haematology, King's College Hospital, London, UK., Roddie C; University College London Hospitals, London, UK.; UCL Cancer Institute, University College London, London, UK., Kirkwood AA; Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, UCL, London, UK., Chaganti S; Queen Elizabeth Hospital, Birmingham, UK., Norman J; Department of Haematology, Manchester Royal Infirmary, Manchester, UK., Lugthart S; University Hospitals Bristol and Weston, Bristol, UK., Osborne W; Freeman Hospital, Newcastle, UK.; Newcastle University, Newcastle, UK., Gibb A; Department of Medical Oncology, The Christie Hospital, Manchester, UK., Gonzalez Arias C; Royal Marsden Hospital, London, UK., Latif A; Queen Elizabeth University Hospital, Glasgow, UK., Uttenthal B; Department of Haematology, Addenbrooke's Hospital, Cambridge, UK., Seymour F; St. James's Hospital, Leeds, UK., Jones C; Department of Haematology, University Hospital of Wales, Cardiff, UK., Springell D; University College London Hospitals, London, UK., Brady JL; Guy's and St Thomas' NHS Foundation Trust, London, UK., Illidge T; Cancer Sciences, University of Manchester Christie NHS Trust, Manchester NIHR BRC, Manchester, UK., Stevens A; Queen Elizabeth Hospital, Birmingham, UK., Alexander E; Royal Marsden Hospital, London, UK., Hawley L; University Hospitals Bristol and Weston, Bristol, UK., O'Rourke N; Queen Elizabeth University Hospital, Glasgow, UK., Bedi C; Western General Hospital, Edinburgh, UK., Prestwich R; St. James's Hospital, Leeds, UK., Frew J; Freeman Hospital, Newcastle, UK., Burns D; Queen Elizabeth Hospital, Birmingham, UK., O'Reilly M; University College London Hospitals, London, UK., Sanderson R; Department of Haematology, King's College Hospital, London, UK., Sivabalasingham S; University College London Hospitals, London, UK., Mikhaeel NG; Guy's and St Thomas' NHS Foundation Trust, London, UK.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Aug; Vol. 205 (2), pp. 483-494. Date of Electronic Publication: 2024 Apr 09.

Healthy tissue metabolism assessed by [ ¹⁸ F]FDG PET/CT as a marker of prognosis and adverse events in advanced Hodgkin lymphoma patients.

Autor: Malaih AA; King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, Kings Health Partners, London, UK.; Radiologic Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia., Kirkwood AA; Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK., Johnson P; Cancer Research UK Centre, University of Southampton, Southampton, UK., Radhakrishnan V; Cancer Care Group, University Hospital of Southampton, Southampton, UK., Fischer BM; King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, Kings Health Partners, London, UK.; Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Barrington SF; King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, Kings Health Partners, London, UK. sally.barrington@kcl.ac.uk.

Publikováno v: Scientific reports [Sci Rep] 2024 Jun 01; Vol. 14 (1), pp. 12613. Date of Electronic Publication: 2024 Jun 01.

Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.

Autor: Oporto Espuelas M; Infection, Immunity and Inflammation, UCL Great Ormond Ormond Street Institute of Child Health, London, UK. m.oporto@ucl.ac.uk., Burridge S; Department of Haematology, Great Ormond Street Hospital, London, UK., Kirkwood AA; Cancer Research UK & Cancer Trials Centre, UCL, London, UK., Bonney D; Department of Blood and Bone Marrow Transplant, Royal Manchester Children's Hospital, Manchester, UK., Watts K; Department of Blood and Bone Marrow Transplant, Royal Manchester Children's Hospital, Manchester, UK., Shenton G; Great North Children's Hospital, Newcastle upon Tyne, UK., Jalowiec KA; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., O'Reilly MA; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., Roddie C; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., Castleton A; Department of Haematology, The Christie Hospital NHS Foundation Trust, Manchester, UK., Clesham K; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., Nicholson E; Department of Haematology/Bone Marrow Transplantation, The Royal Marsden NHS Foundation Trust, London, UK.; Institute of Cancer Research, London, UK., Alajangi R; Department of Haematology/Bone Marrow Transplant, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK., Prabhu S; Department of Haematology/Bone Marrow Transplant, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK., George L; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK., Uttenthal B; Cambridge University Hospital NHS Foundation Trust, Cambridge, UK., Gabelli M; Department of Bone Marrow Transplant, Great Ormond Street Hospital, London, UK.; Pediatric Onco-hematology and Hematopoietic Stem Cell Transplantation, Woman and Child Health Department, University of Padova, Padua, Italy., Neill L; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., Besley C; Department of Haematology/Bone Marrow Transplant, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK., Chaganti S; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK., Wynn RF; Department of Blood and Bone Marrow Transplant, Royal Manchester Children's Hospital, Manchester, UK., Bartram J; Department of Haematology, Great Ormond Street Hospital, London, UK., Chiesa R; Department of Bone Marrow Transplant, Great Ormond Street Hospital, London, UK., Lucchini G; Department of Bone Marrow Transplant, Great Ormond Street Hospital, London, UK., Pavasovic V; Department of Haematology, Great Ormond Street Hospital, London, UK., Rao A; Department of Haematology, Great Ormond Street Hospital, London, UK., Rao K; Department of Bone Marrow Transplant, Great Ormond Street Hospital, London, UK., Silva J; Department of Bone Marrow Transplant, Great Ormond Street Hospital, London, UK., Samarasinghe S; Department of Haematology, Great Ormond Street Hospital, London, UK., Vora A; Department of Haematology, Great Ormond Street Hospital, London, UK., Clark P; NHS England, London, UK., Cummins M; Bristol Royal Hospital for Children, Bristol, UK., Marks DI; Department of Haematology, University Hospitals Bristol, Bristol, UK., Amrolia P; Infection, Immunity and Inflammation, UCL Great Ormond Ormond Street Institute of Child Health, London, UK.; Department of Bone Marrow Transplant, Great Ormond Street Hospital, London, UK., Hough R; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., Ghorashian S; Department of Haematology, Great Ormond Street Hospital, London, UK.; Developmental Biology and Cancer, UCL Great Ormond Ormond Street Institute of Child Health, London, UK.

Publikováno v: Blood cancer journal [Blood Cancer J] 2024 Apr 15; Vol. 14 (1), pp. 66. Date of Electronic Publication: 2024 Apr 15.